Concepedia

Andrew G. Popplewell

AG

19

Publications

1.6K

Citations

16

H-Index

1989

Active since

Affiliations

UCB Pharma (United Kingdom)(Current)

University of Southampton

King's College London

University of Edinburgh

UCB Pharma (Belgium)

Andrew G. Popplewell is an author at UCB Pharma (United Kingdom) specializing in medicine, antibody engineering, and natural sciences.

Top concepts

Publications per year

1989–2021

19

Publications

19

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

Michael S. Ominsky, Fay Vlasseros, Jacquelin Jolette et al. · Journal of Bone and Mineral Research · 2010 · 410 citations · Full text

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 354 citations · Full text

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

Jean‐Philippe Courade, Rachel Angers, Georges Mairet‐Coello et al. · Acta Neuropathologica · 2018 · 133 citations · Full text

Prolonged in Vivo Residence Times of Antibody Fragments Associated with Albumin

Bryan John Smith, Andrew G. Popplewell, Dee Athwal et al. · Bioconjugate Chemistry · 2001 · 92 citations

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22

John F. DiJoseph, Andrew G. Popplewell, Simon Tickle et al. · Cancer Immunology Immunotherapy · 2004 · 88 citations · Full text

, , +9

Rows per page

1–5 of 19